FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024710836> ?p ?o ?g. }

• W3024710836 endingPage "750" @default.
• W3024710836 startingPage "745" @default.
• W3024710836 abstract "Objective: To evaluate the clinical characteristics and survival outcomes of patients with de novo grade 3 or transformed follicular lymphoma (FL). Methods: Fifty-two patients treated at Peking University Cancer Hospital between January 2009 and September 2017 were assessed, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. Baseline characteristics, survival and prognostic factors were analyzed. Results: ① Twenty-six male and 26 female patients were enrolled, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. ②The 3-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 56.0% and 80.6%, respectively. Patients with international prognostic index (IPI) score 0-1 demonstrated significantly better 3-year PFS (80.3% vs 20.1%; t=18.902, P<0.001) and OS (95.7% vs 57.0%; t=10.406, P<0.001) than patients with IPI score 2-3. Three-year PFS (94.1% vs 37.2% vs 25.2%; P=0.002) and OS (100.0% vs 76.0% vs 59.8%; P=0.020) were also significantly different among patients with FLIPI 1 score 0-1, 2, ≥3. FLIPI 2 score was also identified as a prognostic factor for 3-year PFS (68.4%, 0, 0; P=0.001) and OS(87.5%, 76.2%, 0; P=0.003). ③Multivariate analysis indicated a significant association of PFS (HR=3.536, P=0.015) and OS (HR=15.713, P=0.015) with IPI. FLIPI 2 was associated with OS (score 0-1, HR=0.078, P=0.007; score 2, HR=0.080, P=0.022). Conclusion: De novo grade 3 or transformed FL might be a group of curable disease with current treatment strategies. IPI is still a prognostic tool in this scenario.目的： 探讨初治3级或伴有大B细胞转化滤泡淋巴瘤（FL）患者的临床特征及预后。 方法： 收集2009年1月至2017年9月在北京大学肿瘤医院诊断治疗的52例FL患者资料，对患者的基本临床特征、生存及预后因素进行统计学分析。 结果： ①52例患者中，男女各26例，其中3A级28例，3B级13例，伴大B细胞转化11例。②整组患者的3年无进展生存（PFS）率为56.0%，3年总生存（OS）率为80.6%。IPI评分0~1分者较2~3分者的3年PFS率（80.3%对20.1%，t=18.902，P<0.001）和OS率（95.7%对57.0%，t=10.406，P<0.001）高；FLIPI 1评分低、中、高危组患者的3年PFS率分别为94.1%、37.2%、25.2%（P=0.002），3年OS率分别为100%、76.0%、59.8%（P=0.020），FLIPI 2评分低、中、高危组患者的3年PFS率分别为68.4%、0、0（P=0.001），3年OS率分别为87.5%、76.2%、0（P=0.003），差异均有统计学意义。③多因素分析显示，IPI评分≥2分是影响患者PFS（HR=3.536，P=0.015）和OS（HR=15.713，P=0.015）的不良预后因素；FLIPI 2评分与患者OS（以≥3分为参照，0~1分：HR=0.078，P=0.007；2分：HR=0.080，P=0.022）显著相关。 结论： 以现有治疗手段，初治高级别FL和伴大B细胞转化FL有可能治愈，IPI评分仍可以预测该组患者预后。." @default.
• W3024710836 created "2020-05-21" @default.
• W3024710836 creator A5003318386 @default.
• W3024710836 creator A5004358361 @default.
• W3024710836 creator A5004565426 @default.
• W3024710836 creator A5004803637 @default.
• W3024710836 creator A5011803798 @default.
• W3024710836 creator A5018352165 @default.
• W3024710836 creator A5028076162 @default.
• W3024710836 creator A5042235039 @default.
• W3024710836 creator A5059916277 @default.
• W3024710836 creator A5061482899 @default.
• W3024710836 creator A5074348362 @default.
• W3024710836 creator A5077219071 @default.
• W3024710836 creator A5083037234 @default.
• W3024710836 creator A5084682076 @default.
• W3024710836 date "2018-09-14" @default.
• W3024710836 modified "2023-09-23" @default.
• W3024710836 title "[Clinical characteristics and survival analysis of de novo grade 3 or transformed follicular lymphoma patients]." @default.
• W3024710836 cites W13756131 @default.
• W3024710836 cites W1549102166 @default.
• W3024710836 cites W1554787345 @default.
• W3024710836 cites W1587432558 @default.
• W3024710836 cites W1965098644 @default.
• W3024710836 cites W1970648523 @default.
• W3024710836 cites W1973773204 @default.
• W3024710836 cites W2003909385 @default.
• W3024710836 cites W2030071549 @default.
• W3024710836 cites W2051457079 @default.
• W3024710836 cites W2093967829 @default.
• W3024710836 cites W2119147717 @default.
• W3024710836 cites W2121115367 @default.
• W3024710836 cites W2129200400 @default.
• W3024710836 cites W2141176294 @default.
• W3024710836 cites W2141226562 @default.
• W3024710836 cites W2141681661 @default.
• W3024710836 cites W2310716991 @default.
• W3024710836 cites W2344572856 @default.
• W3024710836 cites W2425760010 @default.
• W3024710836 cites W2598700764 @default.
• W3024710836 cites W4205736005 @default.
• W3024710836 cites W4292465829 @default.
• W3024710836 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2018.09.009" @default.
• W3024710836 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7342259" @default.
• W3024710836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30369186" @default.
• W3024710836 hasPublicationYear "2018" @default.
• W3024710836 type Work @default.
• W3024710836 sameAs 3024710836 @default.
• W3024710836 citedByCount "0" @default.
• W3024710836 crossrefType "journal-article" @default.
• W3024710836 hasAuthorship W3024710836A5003318386 @default.
• W3024710836 hasAuthorship W3024710836A5004358361 @default.
• W3024710836 hasAuthorship W3024710836A5004565426 @default.
• W3024710836 hasAuthorship W3024710836A5004803637 @default.
• W3024710836 hasAuthorship W3024710836A5011803798 @default.
• W3024710836 hasAuthorship W3024710836A5018352165 @default.
• W3024710836 hasAuthorship W3024710836A5028076162 @default.
• W3024710836 hasAuthorship W3024710836A5042235039 @default.
• W3024710836 hasAuthorship W3024710836A5059916277 @default.
• W3024710836 hasAuthorship W3024710836A5061482899 @default.
• W3024710836 hasAuthorship W3024710836A5074348362 @default.
• W3024710836 hasAuthorship W3024710836A5077219071 @default.
• W3024710836 hasAuthorship W3024710836A5083037234 @default.
• W3024710836 hasAuthorship W3024710836A5084682076 @default.
• W3024710836 hasConcept C10515644 @default.
• W3024710836 hasConcept C126322002 @default.
• W3024710836 hasConcept C2777058707 @default.
• W3024710836 hasConcept C2778476033 @default.
• W3024710836 hasConcept C2778559949 @default.
• W3024710836 hasConcept C2779338263 @default.
• W3024710836 hasConcept C2780739268 @default.
• W3024710836 hasConcept C3019894029 @default.
• W3024710836 hasConcept C38180746 @default.
• W3024710836 hasConcept C71924100 @default.
• W3024710836 hasConcept C72563966 @default.
• W3024710836 hasConcept C90924648 @default.
• W3024710836 hasConceptScore W3024710836C10515644 @default.
• W3024710836 hasConceptScore W3024710836C126322002 @default.
• W3024710836 hasConceptScore W3024710836C2777058707 @default.
• W3024710836 hasConceptScore W3024710836C2778476033 @default.
• W3024710836 hasConceptScore W3024710836C2778559949 @default.
• W3024710836 hasConceptScore W3024710836C2779338263 @default.
• W3024710836 hasConceptScore W3024710836C2780739268 @default.
• W3024710836 hasConceptScore W3024710836C3019894029 @default.
• W3024710836 hasConceptScore W3024710836C38180746 @default.
• W3024710836 hasConceptScore W3024710836C71924100 @default.
• W3024710836 hasConceptScore W3024710836C72563966 @default.
• W3024710836 hasConceptScore W3024710836C90924648 @default.
• W3024710836 hasIssue "9" @default.
• W3024710836 hasLocation W30247108361 @default.
• W3024710836 hasOpenAccess W3024710836 @default.
• W3024710836 hasPrimaryLocation W30247108361 @default.
• W3024710836 hasRelatedWork W1975914344 @default.
• W3024710836 hasRelatedWork W2106674962 @default.
• W3024710836 hasRelatedWork W2159986890 @default.
• W3024710836 hasRelatedWork W2413581670 @default.
• W3024710836 hasRelatedWork W2523356095 @default.
• W3024710836 hasRelatedWork W2552441620 @default.

• next